Ernexa Q3 2026: $5.6M Cash, Going-Concern Warning, $12.5M Nine-Month Loss
ERNA is trading near its 52-week low of $1.74 (8.0% above the low) on light trading volume (0.2× avg).
Summary
Ernexa posted a $2.9 million Q3 net loss and held $5.6 million of cash, explicitly flagging that it cannot fund the next twelve months without ATM sales and new financing, while remaining under a Nasdaq panel monitor through May 2027.
Key Events · Earnings and Guidance · ERNA
-
Q3 Loss and Nine-Month Burn
Net loss of $2.9 million for the three months and $12.5 million for the nine months ended September 30, 2026, with $9.6 million of cash used in operating activities.
-
Going-Concern Shortfall Disclosed
Cash of $5.6 million at September 30, 2026 is less than the amount needed for the next twelve months; management expects ATM access to cover a significant portion of the gap and is pursuing other financing.
-
ATM Is the Funding Backstop
Net proceeds of $3.7 million under the $9.2 million ATM as of September 30, 2026, plus 43,700 shares for $0.1 million sold on October 6, 2026, leaving roughly $5.3 million available.
-
Goodwill Fully Impaired
A $2.0 million non-cash goodwill impairment was recorded in the nine months ended September 30, 2026, leaving no goodwill on the balance sheet.
Analysis · ERNA · Life Sciences
Cash of $5.6 million at September 30, 2026 stands against a $12.5 million nine-month net loss and $9.6 million of operating cash burn, and management states plainly that this is less than needed to fund the next twelve months. The plan leans on roughly $5.3 million of remaining ATM capacity plus unspecified additional financings, which makes further share sales the base case rather than a contingency. Operationally the quarter was quiet, with a $2.9 million net loss and no revenue, but the nine-month period carried a $2.0 million non-cash goodwill impairment that wiped the remaining goodwill off the balance sheet. Layered on top is the Nasdaq overhang: the panel's jurisdiction ended September 14, 2026, yet a mandatory monitor runs through May 5, 2027, and any renewed bid-price deficiency triggers an immediate delisting determination. For a company this small, cash runway and listing status are the thesis.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ERNA was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1M. The 52-week trading range was $1.74 to $46.11. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.